Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu, Stephen A. Harrison, Sven Francque, et al.
Gastroenterology (2016) Vol. 150, Iss. 5, pp. 1147-1159.e5
Open Access | Times Cited: 921

Showing 1-25 of 921 citing articles:

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Naga Chalasani, Zobair M. Younossi, Joel E. Lavine, et al.
Hepatology (2017) Vol. 67, Iss. 1, pp. 328-357
Open Access | Times Cited: 6187
Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman, Brent A. Neuschwander‐Tetri, Mary E. Rinella, et al.
Nature Medicine (2018) Vol. 24, Iss. 7, pp. 908-922
Open Access | Times Cited: 3319
Mechanisms of hepatic stellate cell activation
Takuma Tsuchida, Scott L. Friedman
Nature Reviews Gastroenterology & Hepatology (2017) Vol. 14, Iss. 7, pp. 397-411
Closed Access | Times Cited: 2240
Molecular and cellular mechanisms of liver fibrosis and its regression
Tatiana Kisseleva, David A. Brenner
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 18, Iss. 3, pp. 151-166
Closed Access | Times Cited: 1276
Hepatic stellate cells as key target in liver fibrosis
Takaaki Higashi, Scott L. Friedman, Yujin Hoshida
Advanced Drug Delivery Reviews (2017) Vol. 121, pp. 27-42
Open Access | Times Cited: 1186
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update
Annalisa Berzigotti, Emmanuel Tsochatzis, Jérôme Boursier, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 3, pp. 659-689
Open Access | Times Cited: 1144
Liver inflammation and fibrosis
Yukinori Koyama, David A. Brenner
Journal of Clinical Investigation (2017) Vol. 127, Iss. 1, pp. 55-64
Open Access | Times Cited: 1017
Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues
Maurizio Parola, Massimo Pinzani
Molecular Aspects of Medicine (2018) Vol. 65, pp. 37-55
Open Access | Times Cited: 894
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
Kenneth Cusi, Beverly Orsak, Fernando Bril, et al.
Annals of Internal Medicine (2016) Vol. 165, Iss. 5, pp. 305-305
Closed Access | Times Cited: 856
NAFLD and diabetes mellitus
Herbert Tilg, Alexander R. Moschen, Michael Roden
Nature Reviews Gastroenterology & Hepatology (2016) Vol. 14, Iss. 1, pp. 32-42
Closed Access | Times Cited: 846
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Konstantin Kazankov, Simon Mark Dahl Baunwall, Karen Louise Thomsen, et al.
Nature Reviews Gastroenterology & Hepatology (2018) Vol. 16, Iss. 3, pp. 145-159
Closed Access | Times Cited: 742
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
Norbert Stefan, Hans‐Ulrich Häring, Kenneth Cusi
The Lancet Diabetes & Endocrinology (2018) Vol. 7, Iss. 4, pp. 313-324
Closed Access | Times Cited: 732
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Jun Guo, Xiuqing Huang, Lin Dou, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 690
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Mohammed Eslam, Shiv Kumar Sarin, Vincent Wai‐Sun Wong, et al.
Hepatology International (2020) Vol. 14, Iss. 6, pp. 889-919
Open Access | Times Cited: 646
PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD
Barbara Gross, Michał Pawlak, Philippe Lefèbvre, et al.
Nature Reviews Endocrinology (2016) Vol. 13, Iss. 1, pp. 36-49
Closed Access | Times Cited: 640
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
Scott L. Friedman, Vlad Ratziu, Stephen A. Harrison, et al.
Hepatology (2017) Vol. 67, Iss. 5, pp. 1754-1767
Open Access | Times Cited: 613
Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases
Varman T. Samuel, Gerald I. Shulman
Cell Metabolism (2017) Vol. 27, Iss. 1, pp. 22-41
Open Access | Times Cited: 608
Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
Naoto Fujiwara, Scott L. Friedman, Nicolas Goossens, et al.
Journal of Hepatology (2017) Vol. 68, Iss. 3, pp. 526-549
Open Access | Times Cited: 603
Current and future pharmacological therapies for NAFLD/NASH
Yoshio Sumida, Masashi Yoneda
Journal of Gastroenterology (2017) Vol. 53, Iss. 3, pp. 362-376
Open Access | Times Cited: 601
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Nadia Bougarne, Basiel Weyers, Sofie Desmet, et al.
Endocrine Reviews (2018) Vol. 39, Iss. 5, pp. 760-802
Open Access | Times Cited: 591
FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
Philip N. Newsome, M. Sasso, Jonathan J Deeks, et al.
˜The œLancet. Gastroenterology & hepatology (2020) Vol. 5, Iss. 4, pp. 362-373
Open Access | Times Cited: 591
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison, Mustafa R. Bashir, Cynthia D. Guy, et al.
The Lancet (2019) Vol. 394, Iss. 10213, pp. 2012-2024
Closed Access | Times Cited: 580
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 9, pp. 599-612
Closed Access | Times Cited: 580
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 578
PPAR control of metabolism and cardiovascular functions
David Montaigne, Laura Butruille, Bart Staels
Nature Reviews Cardiology (2021) Vol. 18, Iss. 12, pp. 809-823
Closed Access | Times Cited: 568
Page 1 - Next Page

Scroll to top